comparemela.com

Latest Breaking News On - Scott braunstein - Page 6 : comparemela.com

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 Earnings Call Transcript

Operator: Greetings and welcome to the Marinus Pharmaceuticals Third Quarter 2023 Financial Results and Business Update Call. [Operator Instructions].

Texas
United-states
Australia
Canada
China
American
Joseph-hulihan
Daniel-gossett
Steven-pfanstiel
Scott-braunstein
Brian-abrahams
Christy-shafer

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

China
Scott-braunstein
Orion-corporation
Exchange-commission
China-national-medical-products-administration
Marinus-pharmaceuticals-provides-business
Marinus-access-program
Second-generation-product-development
Biomedical-advanced-research
Marinus-pharmaceuticals
Administration-for-strategic-preparedness
Human-services

Marinus Pharmaceuticals (MRNS) Scheduled to Post Earnings on Tuesday

Marinus Pharmaceuticals (NASDAQ:MRNS – Get Free Report) is set to release its earnings data before the market opens on Tuesday, November 7th. Analysts expect Marinus Pharmaceuticals to post earnings of ($0.67) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link. Marinus Pharmaceuticals […]

Canada
Scott-braunstein
Robertw-baird
Steven-pfanstiel
Earnings-history-for-marinus-pharmaceuticals
Marinus-pharmaceuticals-stock-performance
Securities-exchange-commission
Royal-bank
Marinus-pharmaceuticals
Institutional-trading-of-marinus-pharmaceuticals
Marinus-pharmaceuticals-inc
Ameritas-investment-partners-inc

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $21.50 Consensus Price Target from Brokerages

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. […]

Canada
Robertw-baird
Scott-braunstein
Steven-pfanstiel
Life-insurance-co
Nasdaq
Securities-exchange-commission
Marinus-pharmaceuticals-inc
Marinus-pharmaceuticals-stock-performance
Royal-bank
Ameritas-investment-partners-inc
Marinus-pharmaceuticals

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.